Measles incidence, vaccine efficacy, and mortality in two urban African areas with high vaccination coverage
- PMID: 2230232
- DOI: 10.1093/infdis/162.5.1043
Measles incidence, vaccine efficacy, and mortality in two urban African areas with high vaccination coverage
Abstract
Measles incidence, vaccine efficacy, and mortality were examined prospectively in two districts in Bissau where vaccine coverage for children aged 12-23 months was 81% (Bandim 1) and 61% (Bandim 2). There was little difference in cumulative measles incidence before 9 months of age (6.1% and 7.6%, respectively). Between 9 months and 2 years of age, however, 6.1% contracted measles in Bandim 1 and 13.7% in Bandim 2. Even adjusting for vaccination status, incidence was significantly higher in Bandim 2 (relative risk 1.6, P = .04). Even though 95% of the children had measles antibodies after vaccination, vaccine efficacy was not more than 68% (95% confidence interval [CI] 39%-84%) and was unrelated to age at vaccination. Unvaccinated children had a mortality hazard ratio of 3.0 compared with vaccinated children (P = .002), indicating a protective efficacy against death of 66% (CI 32%-83%) of measles vaccination. These data suggest that it will be necessary to vaccinate before age 9 months to control measles in hyperendemic urban African areas.
Similar articles
-
Vaccinated children get milder measles infection: a community study from Guinea-Bissau.J Infect Dis. 1986 Nov;154(5):858-63. doi: 10.1093/infdis/154.5.858. J Infect Dis. 1986. PMID: 3772165
-
Reduced childhood mortality after standard measles vaccination at 4-8 months compared with 9-11 months of age.BMJ. 1993 Nov 20;307(6915):1308-11. doi: 10.1136/bmj.307.6915.1308. BMJ. 1993. PMID: 8257884 Free PMC article.
-
Early two-dose measles vaccination schedule in Guinea-Bissau: good protection and coverage in infancy.Int J Epidemiol. 1999 Apr;28(2):347-52. doi: 10.1093/ije/28.2.347. Int J Epidemiol. 1999. PMID: 10342702 Clinical Trial.
-
The resurgence of measles in the United States, 1989-1990.Annu Rev Med. 1992;43:451-63. doi: 10.1146/annurev.me.43.020192.002315. Annu Rev Med. 1992. PMID: 1580601 Review.
-
Population immunity to measles in the United States, 1999.J Infect Dis. 2004 May 1;189 Suppl 1:S91-7. doi: 10.1086/377713. J Infect Dis. 2004. PMID: 15106096 Review.
Cited by
-
Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries.BMJ. 1995 Aug 19;311(7003):481-5. doi: 10.1136/bmj.311.7003.481. BMJ. 1995. PMID: 7647643 Free PMC article.
-
[A survey on vaccine efficacy in the city of Bongor (Chad) and its operational consequences for the vaccination program].Bull World Health Organ. 1997;75(5):427-33. Bull World Health Organ. 1997. PMID: 9480198 Free PMC article.
-
Long-term survival in trial of medium-titre Edmonston-Zagreb measles vaccine in Guinea-Bissau: five-year follow-up.Epidemiol Infect. 1994 Apr;112(2):413-20. doi: 10.1017/s0950268800057836. Epidemiol Infect. 1994. PMID: 8150016 Free PMC article. Clinical Trial.
-
A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine.PLoS One. 2011 Mar 11;6(3):e17748. doi: 10.1371/journal.pone.0017748. PLoS One. 2011. PMID: 21412438 Free PMC article.
-
Non-specific effects of measles, mumps, and rubella (MMR) vaccination in high income setting: population based cohort study in the Netherlands.BMJ. 2017 Aug 30;358:j3862. doi: 10.1136/bmj.j3862. BMJ. 2017. PMID: 28855159 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical